Trial · NCT04847921
Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition
NCT04847921, Phase 2, Phase 3, Terminated, University of Colorado, Denver
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition. Trials, record NCT04847921. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04847921
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition
- NCT number
- NCT04847921
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 11 participants, actual
- Lead sponsor
- University of Colorado, Denver
- Conditions
- Gram-Positive Bacterial Infections, Gram-Positive Bacteraemia, Substance Use Disorders, Intravenous Substance Abuse
- Interventions
- Dalbavancin
- First posted
- 2021-04-19
- Last updated
- 2023-10-19
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | percentage of patients with improvement of the principal infectious diagnosis by clinical assessment within 7 days | 7 days from the start of dalbavancin therapy | improvement in the principal infectious diagnosis by universally accepted clinically observed clinical features (i.e. deffervescence; improved pain, swelling, purulence) |
| Primary | percentage of patients with improvement of the principal infectious diagnosis by clinical assessment within 4 weeks | 4 weeks from the start of dalbavancin therapy | improvement in the principal infectious diagnosis by universally accepted clinically observed clinical features (i.e. deffervescence; improved pain, swelling, purulence) |
| Primary | percentage of patients with improvement of the principal infectious diagnosis by clinical assessment within 6 weeks | 6 weeks from the start of dalbavancin therapy | improvement in the principal infectious diagnosis by universally accepted clinically observed clinical features (i.e. deffervescence; improved pain, swelling, purulence) |
| Primary | percentage of patients with improvement of the principal infectious diagnosis by improvement in imaging within 6 weeks (where applicable) | 6 weeks from the start of dalbavancin therapy | improvement in the principal infectious diagnosis by improved lesions on imaging |
| Primary | percentage of patients with improvement in Erythrocyte Sedimentation Rate (ESR) (where applicable) within 7 days | 7 days from the start of dalbavancin therapy | improvement in ESR (normalization or improvement from index study visit) |
| Primary | percentage of patients with improvement in Erythrocyte Sedimentation Rate (ESR) (where applicable) within 4 weeks | 4 weeks from the start of dalbavancin therapy | improvement in ESR (normalization or improvement from index study visit) |
| Primary | percentage of patients with improvement in Erythrocyte Sedimentation Rate (ESR) (where applicable) within 6 weeks | 6 weeks from the start of dalbavancin therapy | improvement in ESR (normalization or improvement from index study visit) |
| Primary | percentage of patients with improvement in C-Reactive Protein (CRP) (where applicable) within 7 days | 7 days from the start of dalbavancin therapy | improvement in CRP (normalization or improvement from index study visit) |
| Primary | percentage of patients with improvement in C-Reactive Protein (CRP) (where applicable) within 4 weeks | 4 weeks from the start of dalbavancin therapy | improvement in CRP (normalization or improvement from index study visit) |
| Primary | percentage of patients with improvement in C-Reactive Protein (CRP) (where applicable) within 6 weeks | 6 weeks from the start of dalbavancin therapy | improvement in CRP (normalization or improvement from index study visit) |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38249543 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04847921
GET https://conductscience.org/api/trials/v1/NCT04847921/registered